AiVision is a unique telemedicine cloud platform powered by deep learning AI that supports the diagnosis of sight related diseases. It is created with the objective of optimizing the detection and treatment of a highly probable ca...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
Smartscope-X
Affordable accessible and automatic screening solution for...
3M€
Cerrado
RTI2018-095894-B-I00
DESARROLLO DE TECNOLOGIAS INTELIGENTES PARA DIAGNOSTICO DE L...
43K€
Cerrado
Spectra
Spectra A novel diagnostic device to improve retinal imagin...
71K€
Cerrado
RTC-2015-3467-1
Análisis automático de imágenes de fondo de ojo como impleme...
531K€
Cerrado
BES-2014-067889
ANALISIS DE IMAGEN DE FONDO DE OJO PARA CRIBADO AUTOMATICO D...
88K€
Cerrado
iScan
Automated retinal scans for early detection of diabetic eye...
71K€
Cerrado
Información proyecto aiVision
Duración del proyecto: 4 meses
Fecha Inicio: 2019-11-22
Fecha Fin: 2020-03-31
Líder del proyecto
AISCREENINGS
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
AiVision is a unique telemedicine cloud platform powered by deep learning AI that supports the diagnosis of sight related diseases. It is created with the objective of optimizing the detection and treatment of a highly probable cause of blindness in diabetic patients, known as diabetic retinopathy.
Diabetic Retinopathy is the leading cause of blindness affecting the population that is less than 65 years old. After 15 years of significant improvements treating diabetes, 95% of type one diabetic patients and 60% of type 2 diabetic patients suffer from at least a mild and in some cases from severe diabetic retinopathy. In 2015, 415m people suffered from diabetes and this figure will grow up to 640m in 2040. There are 4,2M diabetics in the US, and around 24,000 new cases per year of advanced retinopathy due to diabetes.
AiVision intends to solve this health problem through an improved eye screening medical examination process facilitated by a telemedicine platform and automated algorithms that support diagnosis decision making.
We have gathered a database of more than 107,000 categorized eye fundus screenings which we have use in our algorithms, we have a partnership with the French Orthoptists Syndicate (with 1,000 professionals, it represents 90% of the sector) and are running our first paid pilots in France on 90 hospitals and health centres and working with the WHO in 4 African pilots.
There is a clear willingness to pay from the market actors: orthoptist and ophthalmologists consider that the increase in screened patients will vastly contribute to early detection of signs of retinopathy, allowing for better treatment.
AiVision is the core project of AiScreenings, a start-up founded in 2017 by partners with management, research, medical sciences and IT backgrounds. The company is based at the Polytechnique Institute business incubator (France). With a team of 9, we have generated our first 100.000€ of turnover in 2018 and received a 90.000€ innovation Grant.